Form
Powder
Appearance
Whitetolightyellowcrystallinepowder
Source
Synthetic
WaterContent(KarlFisher)
5.0%-8.0%
OpticalRotation
+84°-+89°
Assay
(OnDriedBasis):Notlessthan95.0%
ResidueOnIgnition
Notmorethan0.2%
HeavyMetals
Notmorethan0.002%
Imipenemisaβ-lactamantibioticinthecarbapenemsubgroupandissolubleinaqueoussolutionat>5mg/mL. Imipenemhasbeenfoundtobeeffectiveagainstextendedspectrumbeta-lactamase(ESBL)producing Enterobacteriaceae;agroupofpathogenicmicrobesresistanttomanyfirstlinebeta-lactamantibioticsandcertaincephalosporins.
TOKU-Eofferstwoformsofimipenem:imipenem(I001)andimipenemw/cilastatin(I002).Cilastatinisachemicalwhichinhibitsthehumanenzymedehydropeptidasewhichdegradesimipenem.
74431-23-5
C12H17N3O4S·H2O
317.36g/mol
β-lactamsinterferewithPBP(penicillinbindingprotein)activityinvolvedinthefinalphaseofpeptidoglycansynthesis.PBP’sareenzymeswhichcatalyzeapentaglycinecrosslinkbetweenalanineandlysineresiduesprovidingadditionalstrengthtothecellwall.Withoutapentaglycinecrosslink,theintegrityofthecellwallisseverelycompromisedandultimatelyleadstocelllysisanddeath.Resistancetoβ-lactamsiscommonlyduetocellscontainingplasmidencodedβ-lactamases.Likemanymembersofthecarbapenemsubgroup,imipenemishighlyresistanttoβ-lactamaseactivity.
-20°C
2941.90.5000
Imipenemisabroadspectrumantibiotictargetingawiderangeofaerobicandanaerobicgrampositiveandgramnegativebacteria.
Powder
Whitetolightyellowcrystallinepowder
Synthetic
5.0%-8.0%
+84°-+89°
(OnDriedBasis):Notlessthan95.0%
Notmorethan0.2%
Notmorethan0.002%